The approval for the vaccine, Abrysvo, in adults aged 18 to 59 was based on the results from a late stage trial in which two doses of the vaccine were teste ...
Activist investors tend to rely on an element of surprise to catch their target company off guard: quietly building up a stake and swooping in with a slide deck full of strategic changes at just the ...
Tuesday's approval makes Abrysvo the first RSV vaccine indicated for adults younger than 50, the biopharmaceutical company said. Last year, it was approved for use by those 60 years and older, as well ...